A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT07154290 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced/Metastatic Non-Small Cell Lung Cancer

Interventions

DRUG: Ubamatamab
DRUG: REGN7075
DRUG: Sarilumab

Sponsor

Regeneron Pharmaceuticals